- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Valneva (VLS)
Track the Valneva share price today and view real-time VLS share price data, including charts, technicals, and key financials. View the VLS premarket stock price ahead of the market session or assess the after hours quote. Explore VLS stock price movements, trading volume, and market activity across the EPA exchange.
What Is the Valneva Stock Price Today?
The Valneva stock price today is 2.278.
What Is the Stock Symbol for Valneva?
The stock symbol for Valneva is ""VLS.""
What Stock Exchange Does Valneva Trade On?
Valneva is listed and trades on the Paris stock exchange.
Is Valneva a Good Stock to Buy?
Determining whether Valneva or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the VLS quote. (ISIN: FR0004056851)
What Is the Valneva Stock Price Today?
The Valneva stock price today is 2.278.
What Is the Stock Symbol for Valneva?
The stock symbol for Valneva is ""VLS.""
What Stock Exchange Does Valneva Trade On?
Valneva is listed and trades on the Paris stock exchange.
Is Valneva a Good Stock to Buy?
Determining whether Valneva or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the VLS quote. (ISIN: FR0004056851)
Currency in EUR
2.278
-0.050(-2.15%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.273
2.359
52 wk Range
2.273
5.415
Trading near 52-week Low
1/3
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.2732.359
52 wk Range
2.2735.415
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
VLS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
5.792
Upside
+154.24%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
- Valneva receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 6K Valneva SE ADR For: 26 March
- Investing.com
- Valneva SE ADR receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Valneva receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Valneva SE ADR receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
6 Buy
0 Hold
1 Sell
Ratings:
7 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 5.792
(+154.24% Upside)
Earnings
Latest Release
17/03/2026
EPS / Forecast
-0.29 / -0.14
Revenue / Forecast
47.69M / 42.47M
Compare VLS to Peers and Sector
Metrics to compare | VLS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVLSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.5x | −3.5x | −0.5x | |
PEG Ratio | 0.00 | −0.23 | 0.00 | |
Price/Book | 3.8x | 0.6x | 2.6x | |
Price / LTM Sales | 2.3x | 24.0x | 3.2x | |
Upside (Analyst Target) | 140.5% | 150.0% | 50.8% | |
Fair Value Upside | Unlock | −6.0% | 7.7% | Unlock |
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, a mosquito-borne viral disease; VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of Europe, and internationally. Valneva SE was founded in 1998 and is based in Saint-Herblain, France.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Valneva (VLS) Stock Price Today?
The Valneva stock price today is 2.278 EUR.
What Stock Exchange Does Valneva Trade On?
Valneva is listed and trades on the Paris Stock Exchange.
What Is the Stock Symbol for Valneva?
The stock symbol for Valneva is "VLS."
What Is the Valneva Market Cap?
As of today, Valneva market cap is 396.160M EUR.
What Is Valneva's Earnings Per Share (TTM)?
The Valneva EPS (TTM) is -0.685.
When Is the Next Valneva Earnings Date?
Valneva will release its next earnings report on 07/05/2026.
From a Technical Analysis Perspective, Is VLS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Valneva Stock Split?
Valneva has split 3 times.
How Many Employees Does Valneva Have?
Valneva has 674 employees.
What is the current trading status of Valneva (VLS)?
As of 30/04/2026, Valneva (VLS) is trading at a price of 2.278 EUR, with a previous close of 2.328 EUR. The stock has fluctuated within a day range of 2.273 EUR to 2.359 EUR, while its 52-week range spans from 2.273 EUR to 5.415 EUR.
What Is Valneva (VLS) Price Target According to Analysts?
The average 12-month price target for Valneva is 5.792 EUR, with a high estimate of 8.5 EUR and a low estimate of 2.15 EUR. 6 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +154.24% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.